• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Shibutani Hiroshi Chris

    6/16/25 6:47:45 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMY alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Shibutani Hiroshi Chris

    (Last) (First) (Middle)
    BRISTOL-MYERS SQUIBB COMPANY
    ROUTE 206 AND PROVINCE LINE ROAD

    (Street)
    PRINCETON NJ 08543

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/09/2025
    3. Issuer Name and Ticker or Trading Symbol
    BRISTOL MYERS SQUIBB CO [ BMY ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, Chief Strategy Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    EXHIBIT LIST: EX-24 Exhibit 24 - Hiroshi Chris Shibutani, GRAPHIC Exhibit 24 - Hiroshi Chris Shibutani
    No securities are beneficially owned.
    /s/ Sophie M. Bail, attorney-in-fact for Hiroshi Chris Shibutani 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY

    DatePrice TargetRatingAnalyst
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    4/22/2025Overweight
    Piper Sandler
    12/16/2024$70.00Hold → Buy
    Jefferies
    12/10/2024$63.00Neutral
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/13/2024Neutral → Outperform
    Daiwa Securities
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    SEC Filings

    See more
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:25:42 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:57 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:02 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care